United States - English - NLM (National Library of Medicine)

espero pharmaceuticals, inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 400 ug - gonitro is indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. do not use gonitro in patients who are taking pde-5-inhibitors, such as avanafil, sildenafil, tadalafil, or vardenafil. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1) ]. do not use gonitro in patients who are taking soluble guanylate cyclase (sgc) stimulators, such as riociguat. concomitant use can cause hypotension. gonitro is contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). gonitro may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e. g. cerebral hemorrhage or traumatic brain injury). gonitro is contraindicated in patients who are allergic to nitroglycerin, other nitrates or nitrites or any excipient. gonitro is contraindicated in

United States - English - NLM (National Library of Medicine)

graceway pharmaceuticals, llc - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 2.5 mg in 1 d - transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease. the onset of action of transdermal nitroglycerin is not sufficiently rapid for this product to be useful in aborting an acute attack. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin is contraindicated in patients who are allergic to it. allergy to the adhesives used in nitroglycerin patches has also been reported, and it similarly constitutes a contraindication to the use of this product.

United States - English - NLM (National Library of Medicine)

cardinal health - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 0.4 mg - nitroglycerin is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin is contraindicated in patients who are allergic to it. sublingual nitroglycerin therapy is contraindicated in patients with early myocardial infarction, severe anemia, increased intracranial pressure, and those with a known hypersensitivity to nitroglycerin. administration of nitrostat is contraindicated in patients who are using a phosphodiesterase-5 (pde-5) inhibitor (e.g., sildenafil citrate, tadalafil, vardenafil hydrochloride) since these compounds have been shown to potentiate the hypotensive effects of organic nitrates.

United States - English - NLM (National Library of Medicine)

rebel distributors corp - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 0.4 mg - nitroglycerin is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin is contraindicated in patients who are allergic to it. sublingual nitroglycerin therapy is contraindicated in patients with early myocardial infarction, severe anemia, increased intracranial pressure, and those with a known hypersensitivity to nitroglycerin. administration of nitrostat is contraindicated in patients who are using a phosphodiesterase-5 (pde-5) inhibitor (e.g., sildenafil citrate, tadalafil, vardenafil hydrochloride) since these compounds have been shown to potentiate the hypotensive effects of organic nitrates.

United States - English - NLM (National Library of Medicine)

sina health inc - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 0.4 mg - nitroglycerin is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin is contraindicated in patients who are allergic to it. sublingual nitroglycerin therapy is contraindicated in patients with early myocardial infarction, severe anemia, increased intracranial pressure, and those with a known hypersensitivity to nitroglycerin. administration of nitrostat is contraindicated in patients who are using a phosphodiesterase-5 (pde-5) inhibitor (e.g., sildenafil citrate, tadalafil, vardenafil hydrochloride) since these compounds have been shown to potentiate the hypotensive effects of organic nitrates.

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 0.4 mg - nitroglycerin is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. allergic reactions to organic nitrates are extremely rare, but they do occur. nitroglycerin is contraindicated in patients who are allergic to it. sublingual nitroglycerin therapy is contraindicated in patients with early myocardial infarction, severe anemia, increased intracranial pressure, and those with a known hypersensitivity to nitroglycerin. administration of nitrostat is contraindicated in patients who are using a phosphodiesterase-5 (pde-5) inhibitor (e.g., sildenafil citrate, tadalafil, vardenafil hydrochloride) since these compounds have been shown to potentiate the hypotensive effects of organic nitrates.

United States - English - NLM (National Library of Medicine)

proficient rx lp - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 0.4 mg - nitroglycerin is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. nitroglycerin is contraindicated in patients who are allergic to it. sublingual nitroglycerin therapy is contraindicated in patients with early myocardial infarction, severe anemia, increased intracranial pressure, and those with a known hypersensitivity to nitroglycerin. administration of nitrostat is contraindicated in patients who are using a phosphodiesterase-5 (pde-5) inhibitor (e.g., sildenafil citrate, tadalafil, vardenafil hydrochloride) since these compounds have been shown to potentiate the hypotensive effects of organic nitrates. do not use nitrostat in patients who are taking the soluble guanylate cyclase stimulator riociguat. concomitant use can cause hypotension.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin 0.4 mg - nitroglycerin is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. nitroglycerin is contraindicated in patients who are allergic to it. sublingual nitroglycerin therapy is contraindicated in patients with early myocardial infarction, severe anemia, increased intracranial pressure, and those with a known hypersensitivity to nitroglycerin. administration of nitrostat is contraindicated in patients who are using a phosphodiesterase-5 (pde-5) inhibitor (e.g., sildenafil citrate, tadalafil, vardenafil hydrochloride) since these compounds have been shown to potentiate the hypotensive effects of organic nitrates. do not use nitrostat in patients who are taking the soluble guanylate cyclase stimulator riociguat. concomitant use can cause hypotension.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin sublingual tablets are indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. do not use nitroglycerin sublingual tablets in patients who are taking pde-5 inhibitors, such as avanafil, sildenafil, tadalafil, vardenafil hydrochloride. concomitant use can cause severe hypotension, syncope, or myocardial ischemia [see drug interactions (7.1)]. do not use nitroglycerin sublingual tablets in patients who are taking the soluble guanylate cyclase stimulators, such as riociguat. concomitant use can cause hypotension. nitroglycerin sublingual tablets are contraindicated in patients with severe anemia (large doses of nitroglycerin may cause oxidation of hemoglobin to methemoglobin and could exacerbate anemia). nitroglycerin sublingual tablets may precipitate or aggravate increased intracranial pressure and thus should not be used in patients with possible increased intracranial pressure (e.g., cerebral hemorrhage or traumatic brain injury). nitroglycerin sublingual tablets are contraindicated in patients who are allergic to nitroglycerin, other nitrates or nitrites or any excipient. nitroglycerin sublingual tablets are contraindicated in patients with acute circulatory failure or shock. risk summary limited published data on the use of nitroglycerin are insufficient to determine a drug associated risk of major birth defects or miscarriage. in animal reproduction studies, there were no adverse developmental effects when nitroglycerin was administered intravenously to rabbits or intraperitoneally to rats during organogenesis at doses greater than 64-times the human dose (see data) . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data animal data no embryotoxic or postnatal development effects were observed with transdermal application in pregnant rabbits and rats at doses up to 80 mg/kg/day and 240 mg/kg/day, respectively, at intraperitoneal doses in pregnant rats up to 20 mg/kg/day from gestation day 7 to 17, and at intravenous doses in pregnant rabbits up to 4 mg/kg/day from gestation day 6 to 18. risk summary sublingual nitroglycerin has not been studied in lactating women. it is not known if nitroglycerin is present in human milk or if nitroglycerin has effects on milk production. the safety and effectiveness of nitroglycerin in pediatric patients have not been established. clinical studies of nitroglycerin sublingual tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

United States - English - NLM (National Library of Medicine)

cosette pharmaceuticals, inc. - nitroglycerin (unii: g59m7s0ws3) (nitroglycerin - unii:g59m7s0ws3) - nitroglycerin ointment 0.4% is indicated for the treatment of moderate to severe pain associated with chronic anal fissure. administration of nitroglycerin ointment is contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate (cgmp)-specific phosphodiesterase type 5 (pde5), such as sildenafil, vardenafil, and tadalafil, as these are shown to potentiate the hypotensive effects of organic nitrates [see 7.1 drug interactions]. nitroglycerin ointment is contraindicated in patients with severe anemia. nitroglycerin ointment is contraindicated in patients with increased intracranial pressure. nitroglycerin ointment is contraindicated in patients who have shown hypersensitivity to it or to other nitrates or nitrites. skin reactions consistent with hypersensitivity have been observed with organic nitrates. pregnancy category c animal reproduction and teratogenicity studies have not been conducted with nitroglycerin ointment. nitroglycerin was not teratogenic when administered by topical or dietary route. there are no adequate and well-controlled studies in pregnant women. nitroglycerin ointment should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. teratology studies in rats and rabbits were conducted with topically applied nitroglycerin ointment at doses up to 80 mg/kg/day and 240 mg/kg/day, respectively. no toxic effects on dams or fetuses were seen at any dose tested. a teratogenicity study was conducted in rats with nitroglycerin administered in the diet at levels up to 1% content (approximately 430 mg/kg/day) on days 6 to 15 of gestation. in offspring of the high-dose group, an increased but not statistically significant incidence of diaphragmatic hernias was noted together with decreased hyoid bone ossification. the latter finding probably reflects delayed development, thus indicating no clear evidence of a potential teratogenic effect of nitroglycerin. it is not known whether nitroglycerin is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when nitroglycerin ointment is administered to a nursing woman. the safety and effectiveness of nitroglycerin ointment in pediatric patients under 18 years of age have not been established. clinical studies of nitroglycerin ointment did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. clinical data from the published literature indicate that the elderly demonstrate increased sensitivity to nitrates, which may be therapeutic but also manifest by more frequent or severe hypotension and related dizziness or fainting. increased sensitivity may reflect the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. patient instructions for use when do i apply the ointment? apply the ointment every 12 hours exactly as your doctor has told you to. how do i apply the ointment? cover your finger with plastic-wrap, a disposable surgical glove or a finger cot. lay the covered finger alongside the 1 inch dosing line marked on the side of the medicine box (see figure below) so that the tip of your finger is at one end of the dosing line. starting at the tip of the finger, squeeze the ointment onto your finger for the same length marked on the box. refer to carton for accurate dosage guide. gently insert the finger with the ointment into the anal canal, up to the first finger joint. carefully smear the ointment around the inner sides of the anal canal. if this cannot be achieved due to pain, application of the ointment should be made directly to the outside of the anus. what do i do after i have applied the ointment? throw away the finger covering in the garbage, out of the reach of children and pets. wash your hands. what are the ingredients in nitroglycerin ointment? active ingredient: nitroglycerin inactive ingredients: propylene glycol, lanolin, sorbitan sesquioleate, paraffin wax and white petrolatum. distributed by: cosette pharmaceuticals, inc. south plainfield, nj 07080 8-0564cplnc2 vc7724 revised: april 2023